Advertisement
Singapore markets closed
  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     
  • S&P 500

    5,003.35
    -68.28 (-1.35%)
     
  • Dow

    37,826.72
    -634.20 (-1.65%)
     
  • Nasdaq

    15,434.09
    -278.66 (-1.77%)
     
  • Bitcoin USD

    63,462.25
    -1,440.87 (-2.22%)
     
  • CMC Crypto 200

    1,372.81
    -9.77 (-0.71%)
     
  • FTSE 100

    8,069.80
    +29.42 (+0.37%)
     
  • Gold

    2,346.90
    +8.50 (+0.36%)
     
  • Crude Oil

    82.41
    -0.40 (-0.48%)
     
  • 10-Yr Bond

    4.7100
    +0.0580 (+1.25%)
     
  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     
  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     
  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Analyst Ratings for Nektar Therapeutics and Peers in March 2018

Analyst Ratings for Nektar Therapeutics and Peers in March 2018

Why Are Investors Excited about Nektar Therapeutics in 2018? Nektar Therapeutics (NKTR) is a biopharmaceutical company with investigational drug candidates for the treatment of cancer, autoimmune disease, and chronic pain. Of the nine analysts covering Nektar Therapeutics in March 2018, four of them have given the stock a “strong buy” rating.